TradeLink Capital’s Standard BioTools LAB Stock Holding History

TradeLink Capital’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-17,300	Closed	-$47K	–	95
2024 Q1	$47K	Buy	+17,300	New	+$41.8K	0.7%	15

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

TradeLink Capital's LAB Position: Q2 2024 in Review

TradeLink Capital sold out of Standard BioTools (LAB) in Q2 2024, closing a stake of 17,300 shares — an estimated $47K sold.

TradeLink Capital first reported a position in LAB in Q1 2024 and held it in 1 quarter. The position peaked at $47K in Q1 2024. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2024.

TradeLink Capital reported no remaining Standard BioTools position as of Q2 2024 after selling out during the quarter.
TradeLink Capital sold 17,300 Standard BioTools shares in Q2 2024, an estimated $47K.
TradeLink Capital first reported a position in Standard BioTools in Q1 2024 and held it in 1 quarter.
TradeLink Capital's Standard BioTools position peaked at $47K in Q1 2024.
144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2024.

Based on TradeLink Capital's 13F filing for Q2 2024, filed 8 Aug 2024.